The present invention relates to a compound of a pharmaceutically acceptable salt thereof of formula (I) wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; (C) a dye moiety; x.sub.1 is a spacer or a chemical single bond covalently connecting (A) to the rest of the molecule; x.sub.2 is a spacer or a chemical single bond covalently connecting (C) to the rest of the molecule. The invention further relates to compositions comprising said compounds as well as a method for detecting neoplastic cells in a sample in vitro with the aid of the compounds or composition. ##STR00001##

Described herein are trehalose analogues. Also described herein are methods of making the trehalose analogues and uses of the analogues. For example, the disclosed trehalose analogues may be useful in the detection of bacteria.

Described herein are trehalose analogues. Also described herein are methods of making the trehalose analogues and uses of the analogues. For example, the disclosed trehalose analogues may be useful in the detection of bacteria.

The invention is directed to a conjugate characterized by high brightness to enable detection of rarely expressed epitopes and release of the label from the epitope to enable downstream applications such as sequential imaging or cell sorting and with the general formula (I) Yn−P1(P2−X.sub.m).sub.o, with X: detection moiety; P1: first enzymatically degradable spacer; P2: second enzymatically degradable spacer; Y: antigen recognizing moiety and n, m, o integers between 1 and 100 with the provision that first spacer P1 and second spacer P2 are not degradable by the same enzyme.

Radioimmunoconjugates including a chelating moiety or a metal complex thereof, a linker, and an FGFR3 targeting moiety. Pharmaceutical compositions of such radioimmunoconjugates and methods of treatment for conditions, e.g., cancer, using such pharmaceutical compositions.

The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II

##STR00001##

or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.

The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II

##STR00001##

or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.

The present disclosure relates to a blood staining patch, a method and device for a blood test using the same, and more particularly, to a patch configured to contain a staining reagent for staining blood and a method and device for economically testing blood using the same. A blood testing method according to an aspect of the present disclosure, which is a blood testing method in which a patch, which includes a mesh structure forming micro-cavities and is configured to contain a staining reagent for staining staining targets present in blood in the micro-cavities, is used to perform a blood test through staining of the staining target, includes placing blood in a reaction region, and providing the staining reagent to the reaction region using the patch configured to contain the staining reagent.

The present disclosure relates to a blood staining patch, a method and device for a blood test using the same, and more particularly, to a patch configured to contain a staining reagent for staining blood and a method and device for economically testing blood using the same. A blood testing method according to an aspect of the present disclosure, which is a blood testing method in which a patch, which includes a mesh structure forming micro-cavities and is configured to contain a staining reagent for staining staining targets present in blood in the micro-cavities, is used to perform a blood test through staining of the staining target, includes placing blood in a reaction region, and providing the staining reagent to the reaction region using the patch configured to contain the staining reagent.

Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof.